RxDoctor Payments Data

Aaron Brooks, DO

Pulmonary Disease · Pensacola, FLNPI 1740775980

Payments from drug & device makers

$3,764in general payments, 2019–2025

Across 53 payments — averaging $71.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • AstraZeneca$201
  • Actelion Pharmaceuticals US, Inc.$141
  • Abbott$131
  • GSK$100
  • Pfizer$69
  • plus $536 from 19 others

What the payments were for

  • Food & beverage$1,26434%
  • Education$2,50066%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,764 in reported general payments places this provider in the 45th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$71,786
Medicare patients
233
Services billed
541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter78$52,731
NucalaMepolizumab12$46,082
Breztri AerosphereBudesonide/Glycopyr/Formoterol33$23,656
Stiolto RespimatTiotropium Br/Olodaterol Hcl17$10,563
SymbicortBudesonide/Formoterol Fumarate34$9,963
Tiotropium Bromide15$5,864
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate19$5,366
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,204
Albuterol Sulfate HfaAlbuterol Sulfate32$1,155
Montelukast Sodium25$277
Prednisone17$64

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala$100$98,81290 claims
AstraZenecaBreztri Aerosphere, Symbicort$201$33,61867 claims
Boehringer IngelheimStiolto Respimat$17$10,56317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →